AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.Vascular system-focused medical device maker reported sales of $80.2 million, up 12.7% year over year, beating the consensus of $74.26 million.The report also revealed:Med Tech net sales were $35.8 million, a 22% increase from $29.3 million in the prior-year period.Growth was driven by Auryon sales during the quarter of $15.6 million, which ...